nCage's Science

TRAP-Cages can act as synthetic viral like particle vaccines driving a greater immune response and lasting protection for patients.

Typical Virus

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam volutpat luctus faucibus. Proin a consectetur felis.

Synthetic VLP

Variants have been tested by nCage and its competition.

Resembles the exterior of a virus and can be used as vaccines.

Antigens mounted only externally.

Very strong immune response already proven in clinical trials.

TRAP-cage

A specific synthetic VLP developed by nCage.

nCage’s solution has programmable opening and closing that supports improved vaccine designs.

Adding the internally mounted antigens creates a chance for even stronger immune response.

A Virus-like structure allows for best-in-class vaccines that has scope for greater efficacy than current approaches.

Virus-like structure is easily recognised by the body and enables the delivery of a large number of antigens close together which increases the immune response.

Synthetic VLPs, unlike viruses, are non-infectious because they contain nogenetic material.

How does nCage make TRAP-cages?

“the scaffold”

TRAP Proteins connected by gold links ensuring high cage stability.

Add-ons

Hooks and antigens are then added to the TRAP-cage.

Synthetic VLP

With antigens mounted both on the interior and exterior of the cage.

Vaccination leading to a strong immune response.

VLP vaccines are the most
effective on the market

Naturally occurring VLPs can significantly increase and extend immunity…

Compared to soluble protein vaccines, in germinal centres protein cages displaying antigen will be able to engage multiple receptors of B cells, which can retrieve and process larger amounts of antigen and have a stronger interaction with the follicular T helper cells.

The end result will be higher levels and longer duration of immunity.

An enhanced response can be particularly important in elderly adult populations that show reducedresponsiveness to conventional vaccines due to immunosenescence.

…but there are only possible for 2 viruses: HPV and HepB

To date, naturally occurring VLPs have been developed into successful vaccines only twice: Cervarix against human papillomavirus (HPV) and Recombivax HB against Hepatitis B.

Synthetic VLPs can be applied across a wide range of viruses to build strong and effective vaccines

Synthetic VLPs can work in the same way as the naturally occurring ones do, but for any virus.

• Possible combination of antigens

• Longer antibody persistence

• Maximised antigen density

• Easy manufacturing